New CAR T-Cell combo trial targets tough hodgkin lymphoma in youth
NCT ID NCT06617286
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests whether giving CD30-targeting CAR T-cells after a strong chemotherapy and stem cell transplant is safe and feasible for children, teens, and young adults with poor-risk classical Hodgkin lymphoma. About 21 participants aged 6 to 29 will receive the treatment. The goal is to see if this approach can help those whose cancer has not responded to or has returned after standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD30 CAR T-cells
What this could lead to
If successful, this could offer a new treatment option for young people with hard-to-treat Hodgkin lymphoma who have not responded to standard therapies.
What could go wrong
This is an early-phase trial with only 21 participants, so results may not apply to everyone. There are risks like cytokine release syndrome and other serious side effects from the CAR T-cells and chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New York Medical College
Valhalla, New York, 10595, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••